Nymox Announces Private Placements of $3 Million
August 09 2017 - 10:30AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to
announce recent completion of private placements with proceeds
totaling US $3.0 million. There were no warrants or fees associated
with the transactions. The placements were with long-term
shareholders of the Company, and will be used for general corporate
purposes.
Nymox announced previously that the Company has
filed for approval in Europe for its new drug Fexapotide Triflutate
for the treatment of BPH (prostate enlargement). The Company has
also reported that there will be subsequent filings in other
jurisdictions for Fexapotide. Nymox has previously announced that
there will be increased new communication activities with the
medical and financial communities, and significant initiatives for
business collaborations to promote the advancement of marketing of
Fexapotide for the treatment of BPH.
The Company announced on August 7 that an
important large symposium and panel discussion of the Company's new
drug Fexapotide Triflutate will be held at the September meeting of
the American Urological Association, Mid-Atlantic Section. The
September symposium at the AUA meeting will feature presentations
from prominent Fexapotide Clinical Trial urologists, and will
include panel discussions of data and results from the U.S.
Fexapotide trials undertaken in 2009-2017. The Chairperson of the
Symposium will be Ronald Tutrone MD, FACS of Chesapeake Urology,
Towson, MD.
Fexapotide has been in development by Nymox for
over 10 years. Clinical trials have shown long-term symptomatic
improvement, long-term reduction in the need for BPH surgery,
long-term reduced prostate cancer risk, and an excellent long-term
safety profile with no sexual side effects in comparison to
available drug treatments. Fexapotide Triflutate is administered at
an office visit and consists of a single painless injection that
takes a few minutes or less, with no requirements of anesthesia, or
analgesia or catheterization. There are none of the typical sexual
and other distressing side effects seen with conventional BPH
treatments. BPH is highly prevalent in middle aged and elderly men,
affecting millions of men world-wide. Existing medical treatments
for BPH generally provide temporary relief only, and are commonly
discontinued by patients due to side effects and little efficacy.
Surgical treatments are effective but often have permanent
retrograde ejaculation as a result, and other problems and risks
are associated.
For more information please contact
info@nymox.com or 800-936-9669.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2016, and its Quarterly Reports.
Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024